Compare BANC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANC | EVO |
|---|---|---|
| Founded | 1941 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 778.3M |
| IPO Year | 2002 | 2007 |
| Metric | BANC | EVO |
|---|---|---|
| Price | $18.51 | $1.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $21.83 | $7.00 |
| AVG Volume (30 Days) | ★ 2.1M | 42.2K |
| Earning Date | 04-22-2026 | 04-08-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | ★ 125.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,818,792,000.00 | N/A |
| Revenue This Year | $13.93 | $1.37 |
| Revenue Next Year | $8.03 | $10.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.33 | $1.72 |
| 52 Week High | $21.93 | $4.27 |
| Indicator | BANC | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 44.51 | 27.66 |
| Support Level | $18.53 | N/A |
| Resistance Level | $19.16 | $1.97 |
| Average True Range (ATR) | 0.38 | 0.04 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 44.93 | 8.11 |
Banc of California Inc is a financial holding company. It offers banking and financial services. Its services include banking services, lending services, and private banking services. Its deposit and banking product and service offerings include checking, savings, money market, certificates of deposit, and retirement accounts. Lending activities are focused on providing financing to California's diverse private businesses, entrepreneurs, and communities, and loans are often secured by California commercial and residential real estate. The company has one reportable segment named Commercial banking.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.